Welcome to our dedicated page for Lexaria Bioscience news (Ticker: LEXX), a resource for investors and traders seeking the latest updates and insights on Lexaria Bioscience stock.
Lexaria Bioscience Corp. develops and licenses DehydraTECH, a patented oral drug delivery formulation and processing platform designed to improve how active pharmaceutical ingredients enter the bloodstream. News about LEXX centers on GLP-1 drug delivery research, DehydraTECH-semaglutide compositions, preclinical and human study updates, intellectual property activity, and pharmaceutical partner evaluations under material transfer arrangements.
Company updates also cover Lexaria's investor communications, oral drug delivery market commentary, and applications of DehydraTECH across pharmaceuticals, nutraceuticals, over-the-counter products, and consumer formats. Recurring themes include bioabsorption, tolerability, blood-brain-barrier delivery, research laboratory activity, and the company's IP licensing business model.
Lexaria Bioscience (NASDAQ:LEXX) has entered into a Material Transfer Agreement with PegBio to evaluate Lexaria's patented DehydraTECH oral drug delivery technology with a proprietary PegBio GLP-1 molecule under development for the GLP-1 market. PegBio will supply the GLP-1 compound, which Lexaria will formulate with DehydraTECH and test for pharmacokinetic performance in animal studies.
The arrangement is independent from Lexaria's existing MTA with another pharmaceutical company. PegBio has a commercial GLP-1 injection approved in China since November 2025 and additional GLP-1 candidates up to Phase II in China and the USA. Lexaria plans to provide an update after the planned studies, including any decisions on potential technology licensing or other business arrangements.
Lexaria Bioscience (Nasdaq:LEXX) will implement a 1-for-15 reverse stock split of its common shares effective 12:01 a.m. EST on August 3, 2026, aiming to increase its share price to regain compliance with Nasdaq’s $1.00 minimum bid requirement under Listing Rule 5550(a)(2).
The split will consolidate approximately 24.79 million issued shares into about 1.65 million shares, with fractional shares rounded up. Authorized shares will decrease from 220 million to about 14.67 million, without changing par value, leaving shareholder ownership percentages unchanged. Options and warrants and their exercise prices will be adjusted proportionally, and LEXX will retain its Nasdaq symbol with a new CUSIP.
Lexaria Bioscience (NASDAQ:LEXX) reported strong business development activity following the 2026 BIO International Convention in San Diego. The company held numerous meetings with potential partners, from small tech firms to large pharmaceutical companies, mainly focused on GLP-1 drug applications and its DehydraTECH technology.
According to Lexaria, discussions emphasized balancing weight-loss efficacy with safety and tolerability, aligning with DehydraTECH capabilities. The company also noted renewed interest in DehydraTECH-CBD and DehydraTECH-nicotine, where it has prior R&D experience, and plans to share further updates when appropriate.
Lexaria Bioscience (NASDAQ:LEXX) began dosing on June 14, 2026 in Human Pilot Study #7 (GLP-1-H26-7), a 5-week trial of two oral DehydraTECH-semaglutide (DHT-sema) formulations versus Novo Nordisk’s Wegovy tablets.
The three-arm study compares SNAC-inclusive DHT-sema tablets and capsules with Wegovy under fasted conditions, aims to reach steady-state semaglutide levels, evaluates safety, tolerability and pharmacokinetics, tests new tablet properties modeled on Rybelsus/Wegovy, and is fully funded from existing resources.
Lexaria Bioscience (NASDAQ:LEXX) began dosing for Animal Study #1 (GLP-1-A26-1) on June 10, 2026, on schedule. The study tests DehydraTECH-semaglutide and DehydraTECH-CBD GLP-1 compositions in Sprague-Dawley rats across 11 arms, with pharmacokinetics and brain drug levels measured.
Results are expected by early September and the work is fully funded. Lexaria has filed 3 new patent applications related to alternative SNAC-like formulations and received its first Australian patent in Family #21 for hypertension (patent #2023302884, expiring April 25, 2043).
Lexaria Bioscience (NASDAQ:LEXX) reports on accelerating GLP-1 adoption and expanding indications for obesity, diabetes and related diseases. Novo’s oral Wegovy has surpassed three million US prescriptions and gained approvals in the UAE and UK, while Lilly reports strong Phase 3 results for retatrutide and oral GLP-1 Foundayo.
Lexaria is advancing its DehydraTECH oral drug delivery platform, targeting improved GLP-1 absorption and fewer gastrointestinal adverse events. In animal studies, DehydraTECH formulations of semaglutide, tirzepatide and liraglutide reduced GI AEs by 31%–100%. New 2026 animal studies will evaluate retatrutide and amycretin with DehydraTECH.
Lexaria Bioscience (NASDAQ:LEXX) has completed dosing in its 2026 Animal Study #2 (GLP-1-A26-2) examining DehydraTECHTM formulations of next-generation GLP-1 drugs retatrutide and amycretin.
The 18-arm study measures pharmacokinetics and tolerability, compares tablets vs capsules, explores sodium caprate-based delivery, and is self-sponsored using existing corporate resources.
Lexaria Bioscience (NASDAQ:LEXX) will attend the BIO International Convention in San Diego from June 22-25, 2026, as part of its broader business development program.
The company reports record-high collaboration interest in its proprietary DehydraTECH oral drug delivery platform and expects a fully booked meeting schedule.
Lexaria Bioscience (NASDAQ:LEXX) received independent ethics board approval for Human Pilot Study #7 (GLP-1-H26-7) to evaluate two oral DehydraTECH-semaglutide (DHT-sema) formulations against Novo Nordisk's Wegovy tablets.
The five-week, fully funded, parallel-group study will assess safety, tolerability and pharmacokinetics under fasted conditions, including first-time multi-week SNAC-inclusive tablet and capsule DehydraTECH compositions.
Lexaria Bioscience (NASDAQ:LEXX) released the second episode of its investor series on May 7, 2026, featuring CEO Rich Christopher discussing a Material Transfer Agreement extension through year-end 2026 with a global pharmaceutical partner and the company’s 2026 GLP-1 research priorities. The episode outlines plans to generate clinical data this year and continued business development activity tied to DehydraTECH and oral drug delivery programs.
Additional episodes will cover the clinical pipeline, intellectual property, and commercial strategy.